BridgeMD
The SORT OUT XII DAPT Duration Trial
EU CTIS ID: 2024-515236-69-00
What this study is testing
To compare short term antiplatelet therapy to guideline dual antiplatelet therapy duration in patients with acute coronary syndromes treated with an everolimus-eluting stent for bleeding and major adverse cardiovascular or cerebrovascular events
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- All patients aged ≥18 years with acute coronary syndromes who are treated with an everolimus-eluting drug-eluting stent can undergo randomization if they can be treated with prasugrel for 12 months.
You likely can't join if
- Age < 18 years
- Not able to consent to study participating (eg. intubated patients)
- Do not speak Danish
- Life expectancy <1 year
- Allergic to study related treatment
- NOAC or warfarin treatment
See the full eligibility criteria
- All patients aged ≥18 years with acute coronary syndromes who are treated with an everolimus-eluting drug-eluting stent can undergo randomization if they can be treated with prasugrel for 12 months.
- Age < 18 years
- Not able to consent to study participating (eg. intubated patients)
- Do not speak Danish
- Life expectancy <1 year
- Allergic to study related treatment
- NOAC or warfarin treatment
- Contraindication for 12 months prasugrel treatment
- Prior stroke
- Women of childbearing age, may participate in this study only if you are surgically
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.